Previous close | 3,789.50 |
Open | 3,799.95 |
Bid | 3,798.25 x 0 |
Ask | 3,803.00 x 0 |
Day's range | 3,768.20 - 3,831.10 |
52-week range | 3,050.15 - 4,104.00 |
Volume | |
Avg. volume | 13,295 |
Market cap | 1.007T |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 72.46 |
EPS (TTM) | 52.33 |
Earnings date | 18 May 2024 - 22 May 2024 |
Forward dividend & yield | 30.00 (0.79%) |
Ex-dividend date | 11 Aug 2023 |
1y target est | N/A |
Indian pharmaceutical company Divi's Laboratories reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug maker grappled with pricing pressures in key markets like the United States. The company reported a consolidated profit of 3.56 billion rupees ($42.9 million) for the first quarter ended June 30, compared to 7.02 billion rupees a year ago. Analysts, on an average, had expected a profit of 4.17 billion rupees, according to Refinitiv data.